Consumer medicine information

APX-Mirtazapine

Mirtazapine

BRAND INFORMATION

Brand name

APX-Mirtazapine

Active ingredient

Mirtazapine

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using APX-Mirtazapine.

What is in this leaflet

This leaflet answers some common questions about APX-Mirtazapine. It does not contain all the available information.

It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking APX-Mirtazapine against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What APX-Mirtazapine is used for

APX-Mirtazapine is used in the treatment of depression including relapse prevention.

Depression is longer lasting or more severe than "low moods" everyone has from time to time due to the stress of everyday life. It is thought to be caused by a chemical imbalance in parts of the brain. This affects your whole body and can cause emotional and physical symptoms such as feeling low in spirit, loss of interest in activities, unable to enjoy life, poor appetite or overeating, disturbed sleep, often waking up early, loss of sex drive, lack of energy and feeling guilty over nothing.

This medicine corrects this chemical imbalance and may help relieve the symptoms of depression.

Your doctor, however, may prescribe it for another purpose.

Ask your doctor if you have any questions about why it has been prescribed for you.

This medicine is only available with a doctor's prescription.

APX-Mirtazapine is not addictive.

Before you take APX-Mirtazapine

When you must not take it

Do not take APX-Mirtazapine:

  • if you are allergic to medicines containing mirtazapine
  • if you are allergic to any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include skin rash, itching or hives, swelling of the face, lips, mouth, throat or other parts of the body, shortness of breath, wheezing or trouble breathing.

Do not take APX-Mirtazapine if you are taking another medicine for depression called a monoamine oxidase inhibitor (MAOI) or have been taking an MAOI within the last 14 days. If you stop taking APX-Mirtazapine, do not take MAOI during the next two weeks either. Taking APX-Mirtazapine with an MAOI may cause a serious reaction with a sudden increase in body temperature, extremely high blood pressure and severe convulsions. Examples of this type of medicine include phenelzine, tranylcypromine and selegiline.

Ask your doctor or pharmacist if you are not sure if you are or if you have been taking a MAOI medicine.

Do not take APX-Mirtazapine if the packaging is torn or shows signs of tampering.

Do not take APX-Mirtazapine if the expiry date printed on the pack has passed.

If you are not sure whether you should start taking APX-Mirtazapine, talk to your doctor.

Before you start to take it

Do not give APX-Mirtazapine to a child or adolescent. The safety of APX-Mirtazapine in patients under 18 years has not been established.

Tell your doctor if:

  1. you are allergic to any other medicines, foods, dyes or preservatives
  2. you are pregnant or plan to become pregnant.
Like most medicines of this kind, APX-Mirtazapine is not recommended to be used during pregnancy. Your doctor will discuss the risks and benefits of taking APX-Mirtazapine when pregnant.
  1. you are breastfeeding or wish to breastfeed.
It is not known whether APX-Mirtazapine passes into breast milk.
  1. if you have or have had any medical conditions, especially the following:
  • thoughts of suicide or self-harm
  • epilepsy (fits or convulsions)
  • liver disease such as jaundice
  • kidney disease
  • heart disease
  • low blood pressure
  • certain kinds of heart conditions that may change your heart rhythm, a recent heart attack, heart failure, or take certain medicines that may affect the heart's rhythm.
  • any mental illness (e.g. schizophrenia, manic depression)
  • diabetes
  • glaucoma (increased pressure in the eye)
  • problems in urinating due to an enlarged prostate
  • unexplainable high fever, sore throat and mouth ulcers
  • galactose intolerance
  • glucose-galactose malabsorption

If you have not told your doctor about any of the above, tell them before you take APX-Mirtazapine.

Tell your doctor if you react badly to lactose or milk before you start taking APX-Mirtazapine. APX-Mirtazapine tablets contain lactose.

Taking other medicines

Tell your doctor if you are taking any other medicines, including medicines you buy without a prescription from a pharmacy, supermarket or health food shop.

Some medicines may be affected by APX-Mirtazapine or may affect how well it works. These include:

  • other medicines (e.g. SSRIs, venlafaxine, L-tryptophan, nefazodone) for depression, anxiety, obsessive compulsive disorders or pre-menstrual dysphoric disorder
  • Monoamine Oxidase Inhibitors (such as tranylcypromine, phenelzine, and selegiline)
  • medicines containing St. John's Wort (hypericum perforatum)
  • phenytoin or carbamazepine, medicines used to treat epilepsy
  • benzodiazepines, medicines used to treat anxiety and sleeping problems
  • lithium, a medicine used to treat some psychiatric conditions
  • methylene blue (used to treat high levels of methemoglobin in the blood)
  • tramadol, a pain killer
  • morphine, a medicine for severe pain
  • cetirizine, a medicine for allergies
  • warfarin, a medicine used to prevent blood clotting
  • linezolid or erythromycin, both antibiotics
  • rifampicin, a medicine used to treat tuberculosis
  • medicines used to treat fungal infections such as ketoconazole
  • HIV/AIDS medications
  • cimetidine, a medicine used to treat reflux and stomach ulcers
  • triptans such as sumatriptan, naratriptan and zolmitriptan, medicines used to treat migraine
  • medicines that may affect the heart's rhythm such as certain antibiotics and some anti-psychotics.

Your doctor will tell you what to do if you are taking any of these medicines.

Your doctor and pharmacist may have more information on medicines to be careful with or avoid while taking APX-Mirtazapine.

If you are not sure whether you are taking any of these medicines, check with your doctor or pharmacist.

How to take APX-Mirtazapine

Follow all directions given to you by your doctor and pharmacist. They may differ from the information contained in this leaflet.

How much to take

Your doctor will tell you how much APX-Mirtazapine to take each day. Take exactly the amount your doctor tells you.

The usual starting dose is 15mg per day. Your doctor may slowly increase this dose depending on how you respond to APX-Mirtazapine. The effective dose for most people is usually between 30mg and 45mg per day.

Your doctor may have prescribed a different dose.

If you do not understand the instructions on the box, ask your doctor or pharmacist for help.

When to take it

Take APX-Mirtazapine at about the same time each day.

Your doctor will tell you when to take your tablets.

The tablet(s) should be taken at the same time each day, preferably as a single night-time dose before going to bed; if recommended by your doctor, APX-Mirtazapine may be taken in sub- doses equally divided over the day (once in the morning and once at night-time before going to bed).

How to take it

Swallow the tablet(s), without chewing, together with some water or other fluid.

How long to take it

Keep taking APX-Mirtazapine until your doctor tells you to stop.

For depression, the length of treatment will depend on how quickly your symptoms improve. Most antidepressants take time to work, so do not be discouraged if you don't feel better right away. Some of your symptoms may improve in 1 to 2 weeks but it can take up to 2 – 4 weeks to feel the full benefit of the medicine.

Even when you feel well, you will usually have to take APX-Mirtazapine for 4 to 6 months or even longer to make sure the benefits will last.

If you forget to take it

ONCE DAILY DOSING

If you forget to take the tablet before you go to bed, do not take the missed dose next morning. It may cause drowsiness or sleepiness during the day. Continue treatment in the evening with your normal dose.

TWICE DAILY DOSING

  • Morning dose forgotten - simply take it together with your evening dose.
  • Evening dose forgotten - do not take it with the next morning dose. Continue treatment with your normal morning and evening doses.
  • Both doses forgotten - do not try to make up for the missed tablets. Continue with your usual morning and evening dose the next day.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone Australia 13 11 26 or New Zealand 0800 POISON or 0800 764 766) for advice, or go to Accident and Emergency at your nearest hospital if you think you or anyone else may have taken too much APX-Mirtazapine. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

If you take too many APX-Mirtazapine tablets, you may feel drowsy, dizzy, confused, and agitated.

You may also have changes to your heart rhythm (fast, irregular heartbeat) and/or fainting which could be symptoms of a life- threatening condition known as Torsades de Pointes.

While you are taking APX-Mirtazapine

Things you must do

Tell your doctor immediately if you develop fever, chills, sore throat or mouth ulcers or other signs of frequent infections. Stop taking APX-Mirtazapine and consult with your doctor for a blood test. In rare cases mirtazapine can cause disturbances in the production of blood cells (bone marrow depression). Some people become less resistant to infection because APX-Mirtazapine can cause a temporary shortage of white blood cells (granulocytopenia). In rare cases APX-Mirtazapine can also cause a shortage of red and white blood cells, as well as blood platelets (aplastic anaemia), a shortage of blood platelets (thrombocytopenia) or an increase in the number of white blood cells (eosinophilia). While rare, these symptoms most commonly appear after 4-6 weeks of treatment.

Tell your doctor immediately or go to the nearest hospital for treatment if you have any suicidal thoughts or other mental/mood changes. Occasionally, the symptoms of depression or other psychiatric conditions may include thoughts of harming yourself or committing suicide. Until the full antidepressant effect of your medicine becomes apparent, it is possible these symptoms may increase in the first few weeks of treatment.

Information from clinical trials have shown an increased risk of suicidal behaviour in young adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.

If you or someone you know is showing warning signs of suicide- related behaviour while taking APX-Mirtazapine, contact your doctor or a mental health professional right away or go to the nearest hospital for treatment. These signs include

  • thoughts or talk about death or suicide
  • thoughts or talk of self-harm or harm to others
  • any recent attempts of self-harm
  • increase in aggressive behaviour, irritability or agitation.

All mentions of suicide or violence must be taken seriously. You may find it helpful to tell a relative or close friend that you are depressed and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.

Tell your doctor if you become pregnant while taking this medicine. Do not stop taking your tablets until you have spoken to your doctor.

If you use APX-Mirtazapine until, or shortly before birth, your baby should be supervised for possible adverse effects.

Ask your doctor whether you can breast-feed, while taking APX-Mirtazapine.

Tell your doctor if for any reason you have not taken your medicine exactly as prescribed. Otherwise your doctor may think that it was not effective and change your treatment unnecessarily.

Tell your doctor if you feel the tablets are not helping your condition.

Be sure to keep all of your appointments with your doctor so that your progress can be checked. You may need to have blood tests from time to time.

Before starting any new medicine, tell your doctor or pharmacist that you are taking APX-Mirtazapine.

Tell all doctors, dentists and pharmacists who are treating you that you are taking APX-Mirtazapine.

Things you must not do

Do not drive or operate machinery until you know how APX-Mirtazapine affects you. APX-Mirtazapine may cause drowsiness, dizziness or sleepiness in some people and affect alertness and concentration. If any of these occur, do not drive, operate machinery or do anything else that could be dangerous.

Do not suddenly stop taking APX-Mirtazapine, or lower the dose, without first checking with your doctor.

Do not let yourself run out of medicine over the weekend or on holidays.

Do not stop taking APX-Mirtazapine, even if you feel better, unless advised by your doctor. Suddenly stopping APX-Mirtazapine may cause nausea, headache, dizziness, anxiety, agitation.

Your doctor may want to gradually reduce the amount of APX-Mirtazapine you are taking before stopping completely.

Do not use APX-Mirtazapine to treat any other conditions unless your doctor tells you to.

Do not give this medicine to anyone else, even if their symptoms seem similar to yours or if they have the same condition as you.

Things to be careful of

You are advised not to drink any alcohol while taking APX-Mirtazapine. Combining APX-Mirtazapine and alcohol can make you sleepier and less alert. Your doctor may suggest you avoid alcohol while being treated with this medicine.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking APX-Mirtazapine.

APX-Mirtazapine helps most people with depression, but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Ask your doctor or pharmacist any questions you may have.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

Tell your doctor if you notice any of the following and they bother you:

  • lethargy, drowsiness or sleepiness
  • headache
  • tiredness
  • increase in appetite and weight gain
  • dry mouth
  • nausea, vomiting
  • diarrhoea
  • constipation
  • dizziness
  • dizziness or faintness when getting up quickly from a lying or sitting position (low blood pressure)
  • abnormal sensations in the mouth sensations of numbness in the mouth or swelling in the mouth
  • aggression
  • swollen ankles or feet as a result of fluid accumulation (oedema)
  • rash or skin eruptions
  • nightmares/vivid dreams
  • tingling fingers or toes
  • painful joints
  • back pain
  • muscle aches and pains
  • restless legs
  • abnormal sensation in the skin for example burning, stinging, tickling or tingling
  • urge to move
  • speech disorders
  • difficulty in passing urine (urinary retention)
  • anxiety, insomnia. These may be symptoms of depression
  • increased prolactin hormone levels in blood (hyperprolactinaemia, including symptoms such as enlarged breasts and/or milky nipple discharge)
  • sleepwalking
  • prolonged painful erection of the penis

Tell your doctor immediately, or go to the Accident and Emergency at your nearest hospital if you notice any of the following:

  • suicidal ideation or behaviour
  • epileptic attack (seizures)
  • shaking or tremors
  • sudden muscle contractions (myoclonus)
  • attack of excessive excitability (mania)
  • agitation
  • confusion
  • hallucinations
  • changes to your heart rhythm
  • fainting
  • yellow colouring of eyes or skin; this may suggest disturbance in liver function
  • abdominal pain and nausea; this may suggest inflammation of the pancreas
  • generalised fluid retention with weight gain
  • skin rash, itching or hives; swelling of the face, lips or tongue which may cause difficulty breathing
  • signs of infection such as sudden unexplainable high fever, sore throat and mouth ulcers
  • a combination of symptoms such as fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes unconsciousness and increased salivation (serotonin syndrome)
  • muscle pain, stiffness and/or weakness, darkening or discolouration of the urine (rhabdomyolysis)

Other side effects not listed above may also occur in some patients.

Tell your doctor if you notice anything else that is making you feel unwell.

Ask your doctor or pharmacist if you do not understand anything in this list.

After taking APX-Mirtazapine

Storage

Keep your tablets in their blister pack until it is time to take them. The tablets may not keep as well if you take them out of the blister pack.

Store below 30°C in a dark, dry place.

Do not store APX-Mirtazapine, or any other medicine, in a bathroom or near a sink. Do not leave it in the car or on windowsills. Heat and dampness can destroy some medicines.

Keep this medicine where young children cannot reach it. A locked cupboard at least one-and-a half metres above the ground is a good place to store medicines.

Disposal

Return any unused medicine to your pharmacist.

Medicines should not be disposed of via waste water or household waste.

Product Description

What it looks like

15 mg
Yellow, biconvex capsule shaped film- coated tablets with a score line in between ‘0’ and ‘8’ on one side and ‘A’ debossed on the other side.
AUST R 183398.

30 mg
Reddish brown, biconvex capsule shaped film-coated tablets with a score line in between ‘0’ and ‘9’ on one side and ‘A’ debossed on the other side.
AUST R 183399.

45 mg
White, biconvex capsule shaped film- coated tablets with ‘10’ debossed on one side and ‘A’ debossed on the other side.
AUST R 183400.

*Some of these presentations and pack sizes may not be marketed.

Ingredients

Each tablet contains mirtazapine as the active ingredient.

Other ingredients:

  • lactose monohydrate;
  • hyprolose;
  • maize starch;
  • colloidal anhydrous silica;
  • magnesium stearate;

15 mg tablet also contains Opadry Complete Film Coating System 20A2052560 Yellow.

30 mg tablet also contains Opadry Complete Film Coating System 20A56788 Brown.

45 mg tablet also contains Opadry Complete Film Coating System 20A58806 White.

Contains sugars as lactose.

APX-MIRTAZAPINE 15, 30 & 45 *(15, 30 & 45 mg mirtazapine) are presented in pack sizes of 30 and 60 tablets in PVC/PVdC-Aluminium foil blister strips. Each blister strip contains 10 tablets.

*Some of these pack sizes are not marketed.

Sponsor

Arrow Pharma Pty Ltd
15- 17 Chapel St
Cremorne VIC 3121

Ph: 1800 195 055

This leaflet was prepared in October 2021.

Published by MIMS December 2021

BRAND INFORMATION

Brand name

APX-Mirtazapine

Active ingredient

Mirtazapine

Schedule

S4

 

1 Name of Medicine

The name of the medicine is mirtazapine.

2 Qualitative and Quantitative Composition

Each tablet contains mirtazapine 15 mg , 30 mg or 45 mg.
Excipients of known effect. Lactose monohydrate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

APX-Mirtazapine 15 mg: Yellow, biconvex capsule shaped, film coated tablets with a score line in between 0 and 8 debossed on one side and 'A' on the other side.
APX-Mirtazapine 30 mg: Reddish Brown, biconvex capsule shaped, film coated tablets with a score line in between 0 and 9 debossed on one side and 'A' on the other side.
APX-Mirtazapine 45 mg: White, biconvex capsule shaped film coated tablets with '10' debossed on one side and ‘A’ on the other side.

4 Clinical Particulars

4.9 Overdose

Post-marketing experience concerning overdose with mirtazapine alone indicates that symptoms are usually mild. The symptoms of overdose are an exaggeration of the pharmacological action of mirtazapine and may include symptoms such as dizziness, impaired consciousness (confusion, disorientation, stupor, coma), agitation, tremor, tachycardia and hyper- and hypotension. As with all overdose attempts, the possibility of multiple drug ingestion should be borne in mind. As with antidepressants in general, serious outcomes, including fatalities, are possible at dosages much higher than the therapeutic dose, especially with mixed overdoses.
Overdose management. Cases of overdose should receive appropriate symptomatic and supportive therapy for vital functions.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Mirtazapine was not genotoxic in a series of tests for gene mutation and chromosomal and DNA damage.
Carcinogenicity. An eighteen month carcinogenicity study in mice showed an increase in the development of hepatic tumours in males after mirtazapine treatment at oral doses of 20 mg/kg/day and above. In a two year carcinogenicity study in rats, oral doses of mirtazapine greater than 20 mg/kg/day were associated in males with an increased incidence of thyroid follicular cell adenomas and carcinomas.
Since the only tumours found in carcinogenicity studies with mice and rats were considered to be species-specific, non-genotoxic responses associated with long term treatment with hepatic enzyme inducers, mirtazapine is not expected to possess carcinogenic potential at therapeutic dosages in the clinic.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Mirtazapine is a tetracyclic piperazinoazepine analogue of mianserin, a chemical structure unrelated to tricyclic antidepressants, monoamine oxidase inhibitors or selective serotonin reuptake inhibitors. Mirtazapine is a white or almost white powder, hygroscopic. It is freely soluble in anhydrous ethanol and practically insoluble in water.
Chemical structure. The name of the medicine is mirtazapine.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSMIRTEN.gif Chemical name. (14bRS)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino [2,1-a] pyrido [2,3-c][2] benzazepine.
Molecular Formula: C17H19N3. Molecular Weight: 265.4.
CAS number. [85650-52-8].

7 Medicine Schedule (Poisons Standard)

Schedule 4 (Prescription only medicine).

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/APXMIRST.gif